ADVFN ADVFN

Hot Features

Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Cosmo Pharmaceuticals NV (PK)

Cosmo Pharmaceuticals NV (PK) (CMOPF)

88.248
2.81
(3.29%)
終了 6月18日 5:00AM

Cosmo Pharmaceuticals NV (PK) (CMOPF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

主要統計と詳細

通貨
88.248
( 3.29% )
買値
56.34
売値
174.79
出来高
1
88.248 日の範囲 88.248
75.00 52 週間の範囲 169.90
時価総額
前日終値
85.44
始値
88.248
最終取引時間
財務取引量
US$ 88
VWAP
88.248
平均取引量 (3 か月)
US$ 51,065
発行済株式数
16,190,775
配当利回り
2.1
PER
-335.64
1 株当たり利益 (EPS)
-0.23
歳入
104.17M
純利益
-3.61M

Cosmo Pharmaceuticals NV (PK) について

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal... Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland. 詳細を表示

セクター
Healthcare
業界
Pharmaceuticals
ウェブサイト
本社
Dublin, Ireland
設立
1997
Cosmo Pharmaceuticals NV (PK) is listed in the Healthcare sector of the その他OTC with ticker CMOPF. The last closing price for Cosmo Pharmaceuticals NV (PK) was US$85.44. Over the last year, Cosmo Pharmaceuticals NV (PK) shares have traded in a share price range of US$ 75.00 to US$ 169.90.

Cosmo Pharmaceuticals NV (PK) currently has 16,190,775 shares in issue. The market capitalisation of Cosmo Pharmaceuticals NV (PK) is US$1.43 billion. Cosmo Pharmaceuticals NV (PK) has a price to earnings ratio (PE ratio) of -335.64.
期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.5380.61338501881287.719084.4932586.93856CS
4-7.252-7.5937172774995.5107.809984.4935093.40040951CS
12-13.002-12.8414814815101.25136.3884.49344105.76029292CS
26-37.752-29.9619047619126169.984.49480123.22967855CS
5210.36813.31278890677.88169.975624121.88438988CS
15646.148109.615201942.1169.941.5537115.01606582CS
260-7.752-8.07596169.941.5517112.48502457CS

CMOPF - Frequently Asked Questions (FAQ)

What is the current Cosmo Pharmaceuticals NV (PK) share price?
The current share price of Cosmo Pharmaceuticals NV (PK) is US$ 88.248
How many Cosmo Pharmaceuticals NV (PK) shares are in issue?
Cosmo Pharmaceuticals NV (PK) has 16,190,775 shares in issue
What is the market cap of Cosmo Pharmaceuticals NV (PK)?
The market capitalisation of Cosmo Pharmaceuticals NV (PK) is USD 1.43B
What is the 1 year trading range for Cosmo Pharmaceuticals NV (PK) share price?
Cosmo Pharmaceuticals NV (PK) has traded in the range of US$ 75.00 to US$ 169.90 during the past year
What is the PE ratio of Cosmo Pharmaceuticals NV (PK)?
The price to earnings ratio of Cosmo Pharmaceuticals NV (PK) is -335.64
What is the cash to sales ratio of Cosmo Pharmaceuticals NV (PK)?
The cash to sales ratio of Cosmo Pharmaceuticals NV (PK) is 11.79
What is the registered address of Cosmo Pharmaceuticals NV (PK)?
The registered address for Cosmo Pharmaceuticals NV (PK) is Riverside 2, Dublin, Co. Dublin, D02 KV60
What is the Cosmo Pharmaceuticals NV (PK) website address?
The website address for Cosmo Pharmaceuticals NV (PK) is www.cosmohealthconfidence.com
Which industry sector does Cosmo Pharmaceuticals NV (PK) operate in?
Cosmo Pharmaceuticals NV (PK) operates in the Pharmaceuticals sector

CMOPF 取引

さらに

取引は遅延しています

リアルタイムの取引を取得するには、アカウントをアップグレードしてください

リアルタイムにアップグレード

最近閲覧した銘柄

Delayed Upgrade Clock